Multi-arm, Phase II Clinical Study of Intraperitoneal Injection of Recombinant Human Tumor Necrosis Factor, Bevacizumab Monoclonal Antibody, and Serplulimab for the Treatment of Malignant Ascites Patients With Standard Therapy Failure
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Bevacizumab (Primary) ; Serplulimab (Primary) ; Sonermin (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
Most Recent Events
- 03 Jun 2024 New trial record